PV is an acquired clonal disorder in which somatic mutation of the JAK2 gene—the sole causative gene documented in the current packet—drives uncontrolled hematopoietic proliferation. The JAK2 mutation arises de novo in bone marrow stem cells during an individual's lifetime and is not transmitted through germline inheritance in the typical sporadic presentation of the condition. Inheritance patterns catalogued in MONDO sources include multifactorial and sporadic modes, consistent with the acquired somatic nature of the disease.

Diagnosis of PV is supported by detection of somatic JAK2 mutation—the sole gene recorded in the current knowledge packet—in conjunction with clinical and laboratory findings consistent with the myeloproliferative phenotype. Hallmark features, as catalogued by Orphanet, include elevated red blood cell mass, splenomegaly, and thrombocytosis. The OMIM reference (263300) and GARD entry (7422) provide additional cross-referencing for diagnostic context.

Two FDA-approved treatments with ACTIVE market status are catalogued in the current packet for acquired polycythemia vera. BESREMI (ropeginterferon alfa-2b-njft), approved by the FDA in November 2021, holds both regulatory approval and orphan drug designation specifically for polycythemia vera. JAKAFI (ruxolitinib phosphate), approved by the FDA in November 2011, similarly holds both regulatory approval and orphan drug designation for polycythemia vera. Multiple additional agents hold FDA orphan drug designation for PV but have not received marketing approval. Two previously designated investigational agents have had their orphan designations withdrawn and are not current options in the active investigational pipeline.

Prognosis-specific data are not explicitly characterized in the assembled knowledge packet. The chronic myeloproliferative nature of PV, as defined in OMIM and Orphanet sources, implies an ongoing disease trajectory rather than a self-limited course. Clinical features including splenomegaly, thrombocytosis, and elevated red blood cell mass are catalogued in Orphanet-linked sources as hallmarks of the disease burden.

The research landscape for PV includes multiple active and recruiting clinical trials catalogued in ClinicalTrials.gov, addressing both PV-specific populations and broader myeloproliferative neoplasm cohorts. Phase 2 investigations of novel agents and established-therapy combinations are documented, with gene therapy-linked trials also represented in the intervention summary. Kisho's publication pipeline has classified 193 items in this disease area, encompassing a substantial body of review articles and meta-analyses alongside biomarker studies and trial-linked publications.